Seropositivity of HPV 16 E6 and E7 and the risk of oral cancer

Oral Dis. 2014 Nov;20(8):762-7. doi: 10.1111/odi.12218. Epub 2014 Jan 21.

Abstract

Objectives: The objective of the study was to determine the prevalence of HPV seropositivity among patients with oral squamous cell carcinoma (OSCC) and healthy individuals and to correlate the association between HPV 16 seropositivity and risk of OSCC.

Materials and methods: HPV 16 E6 and E7 plasmids were constructed for the production of recombinant protein, which was used as the antigen in ELISA. HPV ELISA was performed on serum samples from 50 healthy individuals and 50 patients with OSCC.

Results: Using the HPV ELISA, 30% (OR = 2.25, 95% CI = 0.85-5.93) and 18% (OR = 1.61, 95% CI = 0.53-4.92) of patients with oral cancer were found to be HPV 16 E6 and E7 seropositive, respectively. Significant association was found between HPV 16 seropositivity and increased risk of OSCC in men, but not in male subjects. A similar trend was observed in non-betel quid chewers.

Conclusions: Potential associations between HPV 16 E6/E7 seropositivity and oral cancer were revealed in men and non-betel quid chewer subjects, suggesting a possible etiological role of HPV 16 in subgroup of patients with OSCC in Malaysia.

Keywords: E6 and E7 oncoproteins; ELISA; human papillomavirus 16; oral cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alphapapillomavirus / isolation & purification*
  • Carcinoma, Squamous Cell / virology*
  • Case-Control Studies
  • Humans
  • Middle Aged
  • Mouth Neoplasms / virology*
  • Oncogene Proteins, Viral / blood*
  • Papillomavirus E7 Proteins / blood*
  • Repressor Proteins / blood*
  • Risk Factors

Substances

  • E6 protein, Human papillomavirus type 16
  • Oncogene Proteins, Viral
  • Papillomavirus E7 Proteins
  • Repressor Proteins
  • oncogene protein E7, Human papillomavirus type 16